Table 2.
Baseline human papillomavirus (HPV) PCR, cytology, and high-resolution anoscopy (HRA) * results in the study population.
| Variable | Total Cohort of HIV+ MSM (n = 122) |
HIV+ MSM Vaccine (n = 65) |
HIV+ MSM Placebo (n = 57) |
*p |
|---|---|---|---|---|
| PCR of HPV, n (%) | ||||
| LR-HPV | 73 (59.8) | 39 (60) | 34 (59.6) | 0.97 |
| HR-HPV | 90 (73.8) | 46 (70.8) | 44 (77.2) | 0.42 |
| LR and HR HPV, n (%) | 59 (48.4) | 28 (43.1) | 31 (54.4) | 0.21 |
| Number of HR-HPVs (IQR) | 1 (0–3) | 1 (0–2) | 2 (0–3) | 0.22 |
| Number of LR-HPVs (IQR) | 1 (0–2) | 1 (0–2) | 1 (0–2) | 0.94 |
| Genotypes, n (%) | ||||
| HPV6 | 19 (15.6) | 11 (16.9) | 8 (14) | 0.66 |
| HPV11 | 15 (12.6) | 8 (12.3) | 7 (12.3) | 0.99 |
| HPV16 | 30 (24.6) | 15 (23.1) | 15 (26.3) | 0.68 |
| HPV16 species | 46 (37.8) | 22 (33.3) | 24 (38.1) | 0.49 |
| HPV18 | 9 (7.4) | 4 (6.2) | 5 (8.8) | 0.58 |
| HPV18 species | 40 (32.8) | 18 (27.3) | 22 (34.9) | 0.35 |
| Cytology, n (%) | ||||
| Normal | 53 (41.1) | 26 (39.4) | 27 (42.9) | 0.69 |
| LSIL | 60 (46.5) | 34 (51.5) | 26 (41.3) | 0.24 |
| HSIL | 5 (3.9) | 1 (1.5) | 4 (6.3) | 0.21 |
| ASCUS | 11 (8.5) | 5 (7.6) | 6 (9.5) | 0.69 |
| Total Cohort of | HIV+ MSM | HIV+ MSM | ||
| HIV+ MSM | Vaccine | Placebo | ||
| HRA, n (%) | n = 129 | n = 66 | n = 63 | |
| Normal | 67 (51.9) | 33 (50) | 29 (46) | 0.65 |
| LSIL(AIN1) | 62 (48.1) | 33 (50) | 34 (54) | 0.65 |
HRA: high resolution anoscopy. *p: p-value; p < 0.05.